QNRX Financials

Income Statement
MetricQ1 2026Q4 2025Q3 2025Q2 2025Q1 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
5.1M
+13.5%
4.5M
+12.5%
4.0M
+6.0%
3.8M
-4.1%
4.0M
R&D
3.4M
+10.9%
3.1M
+35.8%
2.3M
+11.2%
2.1M
-13.6%
2.4M
SG&A
1.7M
+19.2%
1.4M
-18.1%
1.7M
-0.2%
1.7M
+10.1%
1.6M
Operating Income
-5131210
-13.5%
-4520435
-12.5%
-4019925
-6.0%
-3793179
+4.1%
-3957177
EBITDA
-5106210
-13.6%
-4495435
-12.5%
-3994925
-6.0%
-3768179
+4.2%
-3932177
Net Income
-4997735
-14.9%
-4348373
-10.1%
-3948165
-6.8%
-3695938
+3.0%
-3812179
EPS (Basic)
$-1.77
-2.3%
$-1.73
+74.2%
$-6.71
-6.8%
$-6.28
+3.4%
$-6.50
EPS (Diluted)
$-1.77
-2.3%
$-1.73
+74.2%
$-6.71
-6.8%
$-6.28
+3.4%
$-6.50
Shares (Diluted)
2.8M
+12.8%
2.5M
+326.7%
588.2K
+0.0%
588.2K
+0.3%
586.3K
Quoin Pharmaceuticals, Ltd. American (QNRX) โ€” Financials